Durable response of breast cancer leptomeningeal metastasis to capecitabine monotherapy.
We report a durable (12-month) response to capecitabine monotherapy, shown clinically, by MRI, and by cerebrospinal fluid analysis, in a patient with leptomeningeal metastasis from breast cancer.
Rogers
Lisa R
LR
Hermelin Brain Tumor Center, Department of Neurosurgery, Henry Ford Hospital, Detroit, MI 48202, USA. lrogers@neuro.hfh.edu
Remer
Sandra E
SE
Tejwani
Sheela
S
D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000134:cerebrospinal fluid / Q000188:drug therapy / Q000556:secondary*; D001943:Breast Neoplasms / Q000134:cerebrospinal fluid / Q000188:drug therapy* / Q000556:secondary; D000069287:Capecitabine; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives; D006801:Humans; D008577:Meningeal Neoplasms / Q000134:cerebrospinal fluid / Q000188:drug therapy* / Q000556:secondary*; D009918:Orbital Neoplasms / Q000134:cerebrospinal fluid / Q000188:drug therapy / Q000556:secondary*; D016896:Treatment Outcome
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil